Related Experiment Videos
Hearing loss in chronic myeloid leukemia
Rahul Naithani1, Jagdish Chandra, N N Mathur
1Division of Hematology, Department of Pediatrics, Kalawati Saran Children's Hospital, New Delhi 110001, India. dr_rahul6@hotmail.com
Pediatric Blood & Cancer
|March 12, 2005
Summary
A 12-year-old girl with chronic myeloid leukemia (CML) experienced hearing loss. Hydroxyurea treatment led to objective hearing improvement, suggesting a potential therapeutic benefit for this rare CML complication.
Area of Science:
- Hematology
- Otolaryngology
- Pharmacology
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
- Hearing impairment is a rare but reported complication of CML.
Observation:
- A pediatric patient with CML presented with abdominal pain, fever, hepatosplenomegaly, anemia, and hearing impairment.
- Brainstem evoked response audiometry (BERA) was used to assess hearing function.
Findings:
- The patient was diagnosed with CML in the chronic phase.
- Treatment with hydroxyurea resulted in objective improvement in hearing, as evidenced by BERA.
- This suggests hydroxyurea may be beneficial for CML-associated hearing loss.
Implications:
- Highlights the importance of audiological assessment in CML patients.
- Suggests hydroxyurea as a potential treatment for hearing impairment in CML.
- Warrants further investigation into the pathogenesis of deafness in CML and its management.